Quod SARCOMA?
Rarum sarcoma textus tumor et partem corporis Sarcoma incurrit. Haec includit liposarcoma secretiori parte natium: neurosarcoma, osteosarcoma atque tendo SARCOMA, cutis, musculus, et SARCOMA. Et ideo omnibus, quia circa I% of adult circiter XV% of pueritia cancer et similitudines anorum. In praeter uolgatam locis existentia in potentia Maior sites et rara sunt plus quam LXXX admodum cum mixta anorum histological components in diversis subtypes. Herpesvirus hominis est genus cancer. Herpesvirus hominis formatae a cancellous Malignant tumor, os, cartilago, pinguis, muscle, vasorum sanguineorum, ac TEXTUS.
Tres isti faciunt factors in treatment of valde challenging SARCOMA. Unde valde magni momenti est pro aegris agitur SARCOMA a multidisciplinary peritus quadrigis. Quod bigas indiget ut comprehendo medici, pathologists, radiologists, oncologists, specialist tum etiam valetudinariorum pharmacopolarum et physica therapists. .
Diagnosis SARCOMA
In order to confirm the diagnosis, biopsy is needed to confirm the presence and specific subtype of sarcoma. Because these tumors are very rare and mixed, it is vital that an experienced pathologist examine biopsy samples. The initial diagnostic radiation tests included CT scans and MRI scans to determine the location and type of sarcoma.
Treatment of SARCOMA
The mainstream treatment for localized sarcoma includes complete surgery combined with radiotherapy or no radiotherapy. The need for an experienced surgeon to perform the operation is very important, because the implementation of improper surgery may have an impact on the treatment outcome.
A large number of randomized clinical trials have confirmed that preoperative or postoperative radiotherapy has obvious benefits for sarcoma of the hand and foot and chest wall sarcoma. A recent international randomized clinical trial evaluated the role of preoperative radiotherapy in the treatment of retroperitoneal sarcoma.
In specific sarcoma subtype weeks, multi-agent chemotherapy is an important part of treatment management; these subtypes include Ewing’s sarcoma, osteosarcoma, and rhabdomyosarcoma. The introduction of these subtypes of multi-agent chemotherapy and limb salvage surgery has become a great success in the field of cancer treatment in the past 40 years.
Deploratae a SARCOMA
Infeliciter, non obstante usu optimal treatment pro completum resection quae manu redditur, ad medium circiter L% de aegris / provectus SARCOMA develop firma / metastatic similitudines anorum. Solent metastasis pervadit venas et pulmonis morbo metastatic locum frequentissima.
Et prognosticum eventus in aegris plerumque pauperes metastatic SARCOMA quae praeterita: et pauci sunt treatment options. Autem, recens notitia indicant mediam quisque altiore mollis TEXTUS metastatic salvos aegris cum auctus est a SARCOMA menses circiter XII ad XVIII menses current. Sunt autem plures options praesto curatio patientibus systemica metastatic SARCOMA.
For patients with slow-growing histological subtypes, the monitoring of small / asymptomatic metastatic lesions is an option. Surgical resection is considered when the patient has a separate metastatic lesion, especially when the lesion is in the lungs. Other local treatment strategies may also be considered including radiotherapy, radiofrequency ablation and embolization.
Arbitrio potest agere metastatic laesiones rhoncus ipsum ac dolor Multidisciplinaris perito eget iterum confirmamus. Et maxime cum aegris metastatic SARCOMA, pelagus positum in systemica curatio curatio, maxime chemotherapy.
Lorem targeted per SARCOMA
Targeted therapy drugs have been introduced in the subtype of soft tissue sarcoma called gastrointestinal stromal tumor (GIST), which has become an example of targeted therapy for solid tumors. Most gastrointestinal stromal tumors (GIST) have KIT and PDGFRA gene mutation characteristics. Due to the introduction of these tyrosine kinase inhibitors, the prognosis of patients with metastatic gastrointestinal stromal tumors (GIST) has been greatly improved.
Praeterea imatinib probatus est enim ut summus periculo curatio anorum post resection. Imatinib etiam feliciter usus est in treatment of aliud cuique SARCOMA (qui dicitur dermatofibrosarcoma prominentiis (DFSP)).
Doxorubicin potest esse sola aut cumulative cum adhuc ifosfamide recta curatio ad vexillum, quia prima metastatic SARCOMA mollis TEXTUS. In praeteritum paucos annos tres internationalis eventus fuisse editis Phase III Volume iudiciis aut editis.
Primum iudicium passim lectus orci, vel aegris accipere doxorubicin doxorubicin et ifosfamide. Et hoc iudicium orci nuntiavit nihil interest rates pro altiore salvos et armis et de aegris cum significantly diutius progressum compositum justo, et gratis salvos responsio significantly altior rates.
Secundum iudicium passim lectus orci aegris accipere doxorubicin et ifosfamide analogs (palifosfamide) doxorubicin plus vel placebo. Hic ostendit quod iudicium orci test eventus non significantly diversis arma duorum. Tertium aegris randomized Volume iudicium accipere vel unum et rubore laudabunt doxorubicin gemcitabine / docetaxel. Consequitur diversitatem intellectuum non significant dictum armis.
Praeterea A randomized Volume iudicium comparari gemcitabine / docetaxel et gemcitabine MONOTHERAPY effective constituere liberandum et curatio est ad maxime schedule leiomyosarcoma polymorphic SARCOMA et indistincto.
In MMVII, marine propriae compositis trabectedin fuit approbatae pro usu in Unionis Europaeae. Et secundum quod probat ex duabus diversis timetables ad eventus medicamento tempus in randomized Volume iudicium II. Deinde, a Phase III Volume iudicium ostendit, quod cum aegris provectus / metastatic liposarcoma et leiomyosarcoma erant randomized accipere vel trabectedin diazolid (aegris cum antitumor accepit Huihuan medicinae curatio ante unum et alterum antitumor numerus).
Hic ostendit quod aegros qui accepit orci iudicium trabectedin ostendit progressum, significantly diutius quam liberam salvos eos qui accepit diazolid. Hanc probat ab usu ducitur ad trabectedin per US Cibus et medicamentis Administration in November MMXV.
The oral tyrosine kinase inhibitor pazotinib has been approved based on the results of a randomized clinical trial of patients with soft tissue sarcoma receiving pazotinib or placebo. This clinical trial showed that the pazotinib group had a significant improvement in progression-free survival, but there was no significant difference in overall survival.
In MMXVI et extract marine microtubule precursor eribulin probatus est a US Cibus et medicamentis Administration pro liposarcoma curatio provectus est. Et hoc secundum probat A randomized Volume iudicium patientibus proficiebat scaena III / metastatic liposarcoma leiomyosarcoma et accepto eribulin aut dacrabzine. Hic ostendit, quod in orci iudicio eribulin brachium habet tempus significantly diutius quam altiore salvos dacarbzaine arm.
Conclusio
De cetero fratres sarcomas carcinomata sunt rara coetus mixtisque de ingredients ingens challenges et non faciem, et in medicamento curatio progressio. Quod in omni curatione gastrointestinal Célula tyrosine kinases introductio in secretiori parte natium (SUMMA) iam in exemplum et in solidum targeted curatio anorum.
Praeterea, in praeteritum paucos annos, non aliquid novum additum agentibus systemicis therapeutica options praesto est pro curatio provectus a SARCOMA, inter pazopanib, trabectedin et eribulin. Et internationalis cooperante inter latius orci basic scientists et inquisitores hybrid cancer curatio processus promotus est jugiter ex his ingredients modi.
